Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Goldman Sachs estimates that global spending on non-hardware aspects of artificial intelligence - including data infrastructure, software and organizational redesign - could exceed $1 trillion in the coming years. The bank highlights current U.S. labor costs tied to the AI transition at $150 billion per year, plus $40 billion annually in executive …
ZenaTech announces the establishment of Phoenix Aero LLC in Lviv, Ukraine, as a manufacturing hub for AI-enabled counter-UAS and interceptor drones aimed at Gulf Cooperation Council defense customers. The initiative leverages cost-effective production and real-world testing to meet growing Middle Eastern demand for scalable, affordable defense dron…
Shares of several publicly traded quantum computing companies climbed after Quantum Computing reported first-quarter 2026 results that showed sharply higher revenue driven by recent acquisitions, a wider operating loss and an expanded contract backlog. The results prompted gains in peer stocks including Rigetti, IonQ and D-Wave Quantum.
U.S. equity futures were softer in early Tuesday trading as investors reacted to intensifying tensions in the Middle East and awaited key inflation figures. Premarket movers included sharp declines for GameStop and Hims & Hers Health after deal and earnings disappointments, while Aramark climbed following stronger-than-expected revenue.
New data from MSCI indicates that over 10% of loans held by private credit funds have been marked down by at least 50%, a level MSCI associates with deep borrower distress or imminent restructuring. The report points to a sustained period of relatively high interest rates as a contributing factor. Writedowns are highest since the post-COVID-19 peri…
POET Technologies Inc. named Sandeep Kumar as Chief Operating Officer, effective May 11, 2026. The appointment, which also designates him an Officer of the Corporation and places him directly under the CEO, coincided with a roughly 5% rise in the company’s shares. Dr. Kumar brings more than 18 years of operations experience at Silicon Labs and prio…
MiNK Therapeutics announced clinical data demonstrating that its off-the-shelf, allogeneic iNKT cell therapy, agenT-797, triggers disease-appropriate immune responses without genetic modification. The same cell product activated pro-inflammatory responses in cancer patients and anti-inflammatory effects in ARDS patients from the same manufacturing …
PayPal trades at a low-teens to single-digit earnings multiple with $5.5B in free cash flow and an active buyback program. With margins already targeted by management to improve via cost cuts and share reduction, the stock offers a favorable risk-reward for a mid-term swing trade. Entry, stop and target included.
Collegium Pharmaceutical has finalized its acquisition of AZSTARYS, an ADHD medication, from Corium Therapeutics for approximately $650 million. The acquisition expands Collegium's ADHD product portfolio, leveraging existing commercial infrastructure to accelerate growth. The company has raised its 2026 financial guidance, expecting product revenue…
Two major Wall Street firms opened coverage of Aevex Corp this week with optimistic ratings, pointing to the drone maker's combat-proven product set and manufacturing scale as advantages as defense spending on autonomous systems increases. Analysts from Jefferies and Raymond James issued Buy-equivalent recommendations with price targets of $32 and …
SAB Biotherapeutics announced Q1 2026 financial results and highlighted ongoing enrollment in their registrational Phase 2b SAFEGUARD trial of SAB-142 for type 1 diabetes. The company reported encouraging Phase 1 data showing C-peptide preservation and better glycemic control, secured $95 million from a public offering to fund operations through 20…
Compass Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, announced its participation in two major investor events in May 2026: the H.C. Wainwright 4th Annual BioConnect Investor Conference and the 2026 Stifel Virtual Targeted Oncology Forum. The company will provide webcast presentations and offer one-on-one meetings for i…
Aveanna Healthcare Holdings Inc. announced its participation and presentation at the William Blair 46th Annual Growth Stock Conference on June 2, 2026. The company will showcase its range of pediatric and adult healthcare services, highlighting its focus on providing high-quality, cost-effective care alternatives to prolonged hospitalization.
Harvard Bioscience announced its financial results for Q1 2026, achieving revenues of $20.8 million with a gross margin improvement to 59%. The company remains profitable on an adjusted EBITDA basis and is progressing on manufacturing consolidation to achieve cost efficiencies. Adoption of higher-margin new product innovations (NPI), such as the Me…
BriaCell Therapeutics Corp. reports that over 230 patients have been enrolled in its pivotal Phase 3 Bria-ABC study testing Bria-IMT in combination with an immune checkpoint inhibitor for metastatic breast cancer. The study, which has FDA Fast Track designation, expects to report interim topline overall survival data in 2026, potentially supporting…
Xilio Therapeutics reported strong first-quarter 2026 financial and operational results. The company is on track to submit an IND for XTX501, a bispecific PD-1/masked IL-2 therapy, mid-2026, with Phase 1 trial initiation planned for the second half of 2026. It presented promising preclinical data for XTX601 targeting CLDN18.2 and advanced multi-spe…
TappAlpha has announced surpassing $500 million in assets under management, doubling within just four months. The company's Growth + Income ETF strategies, including TSPY and TDAQ, focus on combining growth exposure with a tax-efficient income overlay. This milestone reflects strong advisor and investor demand for strategies that generate income wi…
Mereo BioPharma disclosed its first quarter 2026 financial results and corporate updates, emphasizing ongoing regulatory discussions regarding setrusumab's potential pediatric use, active partnership talks for alvelestat Phase 3 development, and advancement of vantictumab's Phase 2 trial. Despite not meeting primary endpoints in setrusumab Phase 3 …
Nayax Ltd. announced robust financial results for Q1 2026, reporting a 32% increase in revenue to $106.9 million, organic revenue growth of 26%, and a 43% year-over-year increase in adjusted EBITDA to $13.9 million. The company expanded its installed base to over 1.5 million devices and customer base to 120,000, demonstrating successful scale and r…
Zevra Therapeutics, a commercial-stage biopharmaceutical company focused on rare diseases, announced its executive team will present at the H.C. Wainwright BioConnect Investor Conference to discuss the company's progress and strategic outlook. The presentation underscores Zevra's commitment to advancing its pipeline and broadening patient access to…
BridgeBio Pharma has submitted a New Drug Application (NDA) to the FDA for encaleret, a targeted treatment for autosomal dominant hypocalcemia type 1 (ADH1). The Phase 3 CALIBRATE trial met all primary and key secondary endpoints, demonstrating rapid and durable improvements in calcium regulation and a favorable safety profile. Encaleret may receiv…
Sagimet Biosciences reported strong first quarter 2026 financial results, highlighted by securing $175 million in equity financing to fund operations through 2028. The company announced plans to initiate a Phase 3 clinical trial of its novel acne drug denifanstat in the U.S. in the second half of 2026, targeting moderate to severe acne. Ongoing Pha…
The Kremlin has reiterated Russian President Vladimir Putin’s recent comment that the conflict in Ukraine is drawing to a close, citing groundwork toward a peace process. Kyiv, however, including President Volodymyr Zelenskiy, has expressed scepticism about Moscow’s intentions, and fighting continued despite a short U.S.-mediated ceasefire.
Wendy's Corp. saw its stock jump in premarket trading after a report said Trian Fund Management, headed by Nelson Peltz, has been seeking outside investor support for a possible bid to take the company private. Discussions reportedly included contacts in the Middle East. The firm has not made a formal offer and both Wendy's and Trian declined to pr…
TransUnion's latest report reveals that the median age of renters has risen to 40, with many delaying or foregoing homeownership due to economic factors. This demographic shift presents a strategic growth opportunity for insurers, as these renters demonstrate stable incomes, strong credit profiles, and increasing demand for comprehensive insurance …
